AstraZeneca PLC (NASDAQ:AZN) is considered one of the most undervalued NASDAQ stocks to buy now. Goldman Sachs raised its price target to GBP150.13 as the company awaits results of a Phase 3 trial for efzimfotase alfa, a treatment for hypophosphatasia (HPP). The economic potential of efzimfotase alfa is estimated at $3.7 billion, 85% higher than consensus estimates.

Goldman Sachs expects findings from the HICKORY and CHESTNUT trials soon, completed in July. AstraZeneca PLC (NASDAQ:AZN) is a key player in rare disease and cancer treatments, with a strong reputation in the healthcare industry for its medical advancements. The firm projects peak sales of $3.7 billion for efzimfotase alfa, which falls within the forecasted range of $3–5 billion.

While AstraZeneca PLC (NASDAQ:AZN) shows investment potential, certain AI stocks may offer greater upside with lower downside risk. The company’s work on rare diseases and cancer treatments has earned it a prominent place in the pharmaceutical sector. If you’re interested in AI stocks, consider exploring other options for potential growth and benefits.

Read more at Yahoo Finance: AstraZeneca (AZN) Stock Target Raised as Goldman Sachs Sees $3.7 Billion Drug Potential